The global aspergillosis treatment market was estimated to reach a valuation of US$ 3055.88 Million in the year 2022. With a robust CAGR of 4.9% from 2023 to 2033, this market is expected to reach US$ 3209 Million by 2023 and US$ 5178 Million by 2033.
It is anticipated that the rising prevalence of the target disease and increased attention to the development of innovative medications would favorably impact market expansion. For instance, Chronic Pulmonary Aspergillosis (CPA), a serious health issue that increases morbidity and mortality, is projected to impact approximately three million individuals worldwide, according to research published in the Journal of Fungi in 2016. Also, around 2.5% of patients with asthma also develop allergic bronchopulmonary aspergillosis (ABPA), which affects 4.8 million people globally, according to the Centers for Disease Control and Prevention (CDC). In the upcoming years, there will be a rise in demand for the condition's medications due to the disease's rising prevalence.
The market expansion is being fueled by the wide availability of drugs that are affordably priced, have a better tolerance as well as safety profile, and have little to no side effects. Itraconazole and corticosteroids are suggested treatments for allergic aspergillosis. Voriconazole, Caspofungin, Posaconazole, and Micafungin are other medications used to treat the invasive form of the illness. If a fungal infection results in bleeding from the lungs, therapeutic options include surgical removal of the fungal mass and embolization.
According to illness type, the severe asthma with fungal sensitization (SAFS) segment is anticipated to dominate the market for chronic aspergillosis treatments during the projected period. Moreover, the category is anticipated to rise throughout the projected period due to the growing incidence of asthma around the globe. For instance, according to the Life Leading International Fungal Education, severe asthma affects between 2 and 20% of people with asthma globally, and, depending on how thoroughly they are evaluated, 35 to 50% of these people have SAFS. According to the same source, the conservative number of persons with SAFS is six million. Such factors have been prominent reasons for the expansion of the global market for aspergillosis treatment.
Various new developments related to the innovation of new drugs have been propelling the market for the treatment of aspergillosis. For the treatment of aspergillosis, researchers are looking into and researching newer medication classes. For instance, the first-of-its-kind medication Fosmanogepix from Amplyx Pharmaceuticals is presently undergoing its second phase of clinical trials. The medication functions by preventing the fungus Gwt1 enzyme. Phase 3 clinical studies for Olorofim, another F2G-developed medication, are now being conducted for invasive types of infection. The business got funds for the research and marketing of the medicine totaling USD 70 million in August 2022.
Since leading companies in the market are concentrating on USA Food and Drug Administration (FDA) clearance for the treatment of chronic aspergillosis, the global chronic aspergillosis treatment market is likely to demonstrate consistent growth during the forecast period. For instance, F2G Ltd. reported in June 2020 that its primary first-in-class candidate, olorofim (previously F901318), has received Qualified Infectious Disease Product (QIDP) designation from the USA. Food and Drug Administration (FDA) for the diagnoses of invasive aspergillosis and others. Leading market players are boosting market growth with strategic efforts including the launch of new products, partnerships, collaborations, and licensing agreements. For instance, F2G Ltd and Shionogi & Co., Ltd established a strategic partnership in May 2022 to create and market the novel antifungal agent olorofim for treating invasive aspergillosis (IA) throughout Europe and Asia. This partnership was meant to aid in the drug's global market expansion as well as commercialization. More similar development in the aspergillosis treatment market during the forecast period is anticipated to open up new avenues for the key players in this market.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 3209 Million |
| Expected Market value in 2033 | US$ 5178 Million |
| Growth Rate (2023 to 2033) | 4.9% from 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing prevalence of aspergillosis around the world is expected to drive the growth of the aspergillosis treatment market. Favorable government frameworks are also expected to contribute significant growth towards the growth of aspergillosis treatment market. However, patent expiration of branded therapeutics is expected to restrict the growth of aspergillosis treatment market.
The global market for aspergillosis treatment market is estimated to experience a significant growth during the forecast period due to increasing prevalence of aspergillosis. Based on type, the global aspergillosis treatment market is divided into allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis and cutaneous (skin) aspergilllosis.
Among these, the ABPA is the most type of aspergillosis. Thus, it is expected to generate highest revenue in the forecast period.On the basis of drug class, the global aspergillosis treatment market is segmented into corticosteroids and anti-fungal drugs.
The corticosteroids that are highly preferred are prednisone, prednisolone and methylprednisolone. Antifungals are further classified into voriconazole, itraconazole, caspofungin, micafungin, amphotericin B and isavuconazole. Antifungals such as voriconazole and isavuconazole are expected to be the leading drivers of the global aspergillosis treatment market in the forecast period.
On the basis of distribution channels, the global aspergillosis market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Principal Consultant
Geographically, the aspergillosis treatment market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. The North America is expected to dominate the global aspergillosis treatment market due to increasing government initiatives for diagnosing and treatment of infections.
Europe is expected to have the second largest market for global aspergillosis treatment market due to increasing increasing prevalence of the disease. Additionally, East Asia is expected to observe a substantial growth in the aspergillosis treatment market. However, South Asia is anticipated to experience fastest growth in the aspergillosis treatment market, owing to large volume of untreated patients.
Developing medical infrastructure and increasing awareness of infectious diseases may lead to steady growth in Latin America. In the Middle East and Africa the market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.
Some of the players identified in the aspergillosis treatment market include:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tentatively, the global aspergillosis treatment market has been segmented on the basis of type, drug class and distribution channel.
Explore Healthcare Insights
View Reports
Aspergillosis Treatment Market
